Rational excipient screening to improve LNP stability, reduce aggregation, and protect formulation performance across storage, freeze-thaw, and transport stress.
Lipid nanoparticles (LNPs) are highly sensitive colloidal systems in which small changes in excipient composition can trigger aggregation, particle size drift, payload leakage, PDI increase, osmotic imbalance, or loss of functional activity. For research teams developing RNA, peptide, protein, or small-molecule LNP formulations, excipient selection is not a simple buffer adjustment—it is a formulation design step that directly influences the physical integrity, dispersion behavior, and handling robustness of the nanoparticle system. BOC Sciences provides specialized LNP excipient screening services for sugar, salt, stabilizer, osmolyte, buffer, and injectable LNP excipient evaluation, helping formulation scientists identify excipient combinations that maintain particle size, encapsulation status, colloidal stability, and sample usability under practical development conditions. Our service is designed for teams facing LNP aggregation, freeze-thaw instability, storage instability, shipment-related stress, and unpredictable particle size drift during formulation development.
We provide systematic excipient screening for LNP formulation development, with a focus on stabilizing lipid nanoparticle dispersions under freezing, thawing, refrigerated storage, room-temperature handling, dilution, and transportation stress. Our screening strategy is customized according to LNP composition, payload type, particle size target, buffer environment, and the main instability mode observed in your formulation.
Sugars are widely used to protect LNPs from freezing, drying, and interfacial stress. We screen mono- and disaccharide systems to identify suitable stabilizing environments for liquid, frozen, or lyophilized LNP formulations.
Salt type and ionic strength strongly influence electrostatic interactions, osmotic pressure, and particle-particle repulsion in LNP dispersions. We evaluate salt effects to reduce aggregation risk and improve formulation consistency.
Some LNPs require additional stabilizers to reduce adsorption, vial-wall interaction, interfacial stress, or shear-related aggregation. We evaluate stabilizer compatibility without disrupting lipid architecture or payload retention.
Osmolytes and tonicity modifiers can help balance formulation comfort, osmotic stress, and nanoparticle integrity. We screen osmolyte systems to improve liquid-state robustness and dilution tolerance.
Buffer identity and pH affect lipid ionization, nucleic acid complexation, particle charge, and long-term stability. We design buffer screens to identify environments that preserve LNP structure during storage and handling.
Many LNP projects fail during sample transfer, freeze-thaw cycling, or shipping simulation. We evaluate excipient systems under practical stress conditions to identify formulations with improved handling tolerance.
LNP excipient screening should not only focus on physical stabilization, but also consider compatibility with nucleic acid cargos, biological tolerance, stress protection, and formulation-associated immune response risk. BOC Sciences designs multidimensional screening strategies for mRNA, siRNA, pDNA, circRNA, and other nucleic acid-loaded LNP systems, helping formulation teams identify excipients that support particle stability, cargo protection, and downstream research performance.
Our excipient screening services support diverse LNP systems, including RNA-loaded, peptide-loaded, protein-loaded, and small-molecule-loaded formulations. Screening plans are adapted to the payload's sensitivity, lipid composition, target particle profile, and intended handling route. For clients developing complex nucleic acid or drug-loaded LNPs, excipient selection is often integrated with lipid nanoparticle formulation and downstream lipid nanoparticle stability studies to identify compositions that maintain particle size, dispersion quality, cargo retention, and stress tolerance.
| LNP Formulation Scenario | Excipient Screening Focus and Typical Readouts |
|---|---|
| mRNA-LNPs | Screening of sucrose, trehalose, buffer systems, salts, and stabilizers to support RNA protection, particle dispersion, and post-stress functional retention. |
| siRNA and Oligonucleotide LNPs | Evaluation of excipients that reduce aggregation while preserving nucleic acid association and minimizing leakage after dilution, freezing, or storage. |
| Protein and Peptide LNPs | Compatibility screening for stabilizers, osmolytes, sugars, and buffer systems that protect both nanoparticle dispersion and sensitive macromolecular payloads. |
| Small-Molecule LNPs | Screening of excipient systems that reduce crystallization, phase separation, adsorption, or drug leakage while maintaining nanoparticle size distribution. |
| Injectable LNP Excipient Systems | Osmolality, pH, salt type, sugar concentration, stabilizer compatibility, and visible stability evaluation for injectable-oriented LNP formulation research. |
| Frozen or Lyophilized LNP Candidates | Cryoprotectant and lyoprotectant screening to improve reconstitution, reduce post-thaw aggregation, and maintain particle size after freezing or drying stress. |
| Shipment-Sensitive LNP Samples | Excipient ranking under vibration, agitation, temperature excursion, hold-time, and container-contact stress to identify transport-robust candidates. |
LNP instability often appears as a practical handling problem, but the underlying cause may involve lipid phase behavior, ionic strength, interfacial adsorption, osmotic stress, or payload-lipid interaction. BOC Sciences helps identify the cause and screen excipients that directly address it.
✔ Sample Aggregation After Storage
We screen sugar, salt, buffer, and stabilizer systems to reduce particle-particle attraction and identify conditions that maintain a narrow particle size distribution during storage.
✔ Freeze-Thaw Instability
We compare sucrose, trehalose, mannitol, and combination protectants to identify excipient systems that reduce ice-interface damage, fusion, and post-thaw particle growth.
✔ Particle Size Drift
We track size, PDI, and zeta potential over time to determine whether drift is driven by salt concentration, pH, lipid rearrangement, stabilizer incompatibility, or dilution effects.
✔ Poor Transport Stability
We test excipient candidates under agitation, short-term temperature excursion, and container-contact stress to help reduce shipment-related turbidity or precipitation.
✔ Osmolality or Tonicity Imbalance
We evaluate osmolytes, salts, and tonicity modifiers to balance osmolality while preserving nanoparticle integrity and avoiding excipient-induced aggregation.
✔ Excipient-Induced Payload Leakage
Some stabilizers or ionic environments can disrupt payload association. We monitor encapsulation-related indicators and leakage-sensitive readouts during excipient selection.
We review your LNP composition, payload type, buffer system, current excipients, storage history, particle size data, and observed instability, such as aggregation, post-thaw size increase, precipitation, or loss of dispersion quality.
We construct a tailored screening matrix covering sugars, salts, stabilizers, osmolytes, buffers, pH windows, and concentration gradients. Stress conditions may include freeze-thaw cycling, refrigerated hold, room-temperature exposure, dilution, agitation, or temperature excursion.
Candidate formulations are evaluated by particle size, PDI, zeta potential, osmolality, appearance, turbidity, and payload-retention-related assays. When needed, the screen is paired with lipid nanoparticle characterization, nanoparticle size analysis, and nanoparticle zeta potential analysis.
We deliver a comparative report that ranks excipient candidates, explains likely instability drivers, and recommends practical formulation directions. Selected candidates can be advanced into lipid nanoparticle stability studies or integrated with LNP process optimization for broader formulation refinement.
Challenge: A formulation team developing an mRNA-LNP sample observed a particle size increase from approximately 92 nm to more than 180 nm after one freeze-thaw cycle. The sample also showed visible opalescence and a PDI increase above 0.30, making it unsuitable for further comparative in vitro evaluation.
Diagnosis: Initial analysis indicated that the original buffer contained a low level of cryoprotective excipient and moderate ionic strength, creating a formulation environment vulnerable to ice-interface stress and particle-particle contact during freezing. Zeta potential changes suggested reduced colloidal repulsion after thawing.
Solution: BOC Sciences designed a focused sugar and salt screening panel including sucrose, trehalose, sucrose-trehalose combinations, and reduced ionic-strength buffer variants. Each candidate was tested after controlled freezing, thawing, and short-term refrigerated hold. DLS, PDI, zeta potential, appearance, and RNA accessibility indicators were compared across the matrix. The strongest candidate used a trehalose-sucrose combination with adjusted buffer ionic strength, which improved post-thaw redispersion while preserving the original size profile more effectively than either sugar alone.
Result: The optimized excipient system maintained particle size within approximately 15% of the pre-freeze value, reduced PDI to below 0.20 after thawing, and eliminated visible aggregation in the tested freeze-thaw condition. The client selected this composition for subsequent storage and process refinement studies.
Challenge: A client working on an injectable-oriented LNP formulation observed gradual particle size drift during 2–8 °C storage. The average size increased from approximately 105 nm to 145 nm within two weeks, while the sample remained visually clear during the first few days, making early instability difficult to detect.
Diagnosis: Comparative testing showed that the formulation was sensitive to buffer type and salt concentration. The original buffer provided acceptable initial osmolality but gradually reduced colloidal stability. A mild zeta potential shift and increasing PDI suggested slow particle association rather than immediate lipid precipitation.
Solution: Our team built an excipient matrix covering histidine- and citrate-based buffers, reduced and moderate salt concentrations, sucrose supplementation, glycerol-containing osmolyte conditions, and selected stabilizer levels. Candidates were monitored by DLS, PDI, zeta potential, osmolality, turbidity, and appearance over a storage period. The best-performing condition combined a lower ionic-strength buffer with sucrose and a compatible osmolyte, balancing osmolality while reducing storage-driven particle growth.
Result: The selected excipient condition limited size drift to less than 10 nm over the same observation window and maintained PDI below 0.18. The client used the ranking data to prioritize one lead buffer-excipient composition and two backup compositions for expanded stability comparison.
Instability-Focused DesignWe do not screen excipients randomly. Each panel is built around the client's observed failure mode, such as aggregation, freeze-thaw sensitivity, particle size drift, leakage, or transport instability.
Broad Excipient CoverageOur screening can cover sucrose, trehalose, salts, stabilizers, osmolytes, tonicity modifiers, buffer systems, pH windows, and injectable LNP excipient combinations.
Integrated Analytical ReadoutsExcipient candidates are evaluated using size, PDI, zeta potential, osmolality, appearance, turbidity, and payload-retention-related indicators rather than a single endpoint.
Payload-Specific ExpertiseWe adapt screening logic for mRNA, siRNA, ASO, peptide, protein, antigen, and small-molecule LNPs, recognizing that each payload type responds differently to excipient and buffer changes.
Connection to CQA EvaluationCandidate excipient systems can be further examined through LNP critical quality attributes and QC testing to support deeper comparison of formulation performance.
LNP excipient screening services evaluate how non-lipid formulation components influence lipid nanoparticle stability, RNA protection, particle size, aggregation tendency, and post-processing performance. Although the lipid composition forms the LNP structure, non-lipid excipients such as sucrose, trehalose, mannitol, buffer salts, pH modifiers, osmotic agents, and selected surfactants can strongly affect whether an LNP formulation remains stable during dilution, buffer exchange, freezing, lyophilization, reconstitution, and storage. These services help researchers compare excipient combinations under practical formulation conditions and identify which non-lipid environment best supports colloidal stability, payload retention, and reproducible analytical performance.
In LNP excipient screening, the most relevant non-lipid excipients usually include sugars such as sucrose and trehalose, polyols such as mannitol, buffering systems such as citrate, histidine, Tris, or phosphate-based buffers, osmotic adjustment agents, salts at different concentrations, and low-level stabilizing surfactants when appropriate. Sucrose and trehalose are frequently assessed as cryoprotectants or lyoprotectants because they can help preserve nanoparticle structure during freezing and drying. Mannitol may improve lyophilized cake appearance in some systems, but its crystallization behavior needs careful evaluation because it may not provide the same protective effect as amorphous sugars.
Buffer selection is a central part of LNP excipient screening because pH, ionic strength, salt species, and buffer exchange conditions can influence encapsulation efficiency, RNA leakage, particle size, PDI, and colloidal stability. For nucleic acid-loaded LNPs, a buffer that appears acceptable before processing may perform poorly after freezing, drying, dilution, or reconstitution. Phosphate-containing systems, citrate buffers, histidine buffers, Tris buffers, and low-salt systems may show very different effects depending on LNP composition and storage objective. Screening should therefore compare buffers under realistic process stresses rather than only measuring initial particle size.
Sucrose and trehalose are commonly screened in LNP formulation development because they can protect nanoparticles from freezing- and drying-induced stress. During freezing or lyophilization, water removal and ice formation can promote particle fusion, lipid membrane disruption, RNA exposure, and irreversible aggregation. Sugars can help form a protective amorphous matrix and reduce structural collapse during dehydration and reconstitution. However, the optimal sugar type and concentration depend on lipid composition, RNA payload, LNP concentration, buffer environment, freezing rate, drying cycle, and reconstitution conditions. Therefore, sucrose and trehalose should be evaluated as part of a broader excipient matrix rather than selected by assumption.
LNP excipient screening services should provide comparative data that helps researchers choose a practical non-lipid excipient system rather than a single unsupported recommendation. Typical readouts include particle size, PDI, zeta potential, encapsulation efficiency, free RNA level, pH shift, osmolality, aggregation behavior, freeze-thaw recovery, lyophilization and reconstitution performance, visual appearance, and short-term stress stability. For lyophilized LNPs, additional observations may include cake morphology, reconstitution time, clarity, and post-reconstitution particle recovery. BOC Sciences can design screening matrices around buffer systems, sugars, polyols, salts, and stabilizing agents to identify excipient combinations that best maintain LNP colloidal stability and payload integrity for formulation optimization.
